Figure 5: Pre-treatment tumor RNA sequencing can be leveraged to model aPD1-induced BCR diversity and clinical outcomes.

A) Prediction model applied to a new melanoma patient cohort. Mosaic plot of clinical response by RECIST stratified by model prediction of induced BCR clonotype expansion. BR: Best response, CR: Complete response, MR: Marginal response, PD: Progressed disease, PR: Partial response, SD: Stable disease.

B) Kaplan-Meier curve of progression-free survival stratified by model prediction of induced BCR clonotype expansion in melanoma patients treated with PD1 inhibitor (left) and other, non-PD1 therapies (right).

C) Kaplan-Meier curve of overall survival stratified by model prediction of induced BCR clonotype expansion in melanoma patients treated with PD1 inhibitor (left) and other, non-PD1 therapies (right).